VAXCYTE, INC. Operating Lease, Payments
VAXCYTE, INC. (PCVX) reported Operating Lease, Payments of $3.25 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-05
- VAXCYTE, INC. operating lease, payments for the quarter ending 2026-06-30 was $3.25M, a 4.43% increase year-over-year.
- VAXCYTE, INC. operating lease, payments for the quarter ending 2026-03-31 was $3.71M, a 20.20% increase year-over-year.
- VAXCYTE, INC. operating lease, payments for the quarter ending 2025-12-31 was $3.40M, a 9.44% increase year-over-year.
- VAXCYTE, INC. operating lease, payments for the quarter ending 2025-09-30 was $3.13M, a 13.39% decline year-over-year.
- VAXCYTE, INC. operating lease, payments for fiscal 2025 was $12.73M, a 10.58% increase from fiscal 2024.
- VAXCYTE, INC. operating lease, payments for fiscal 2024 was $11.51M, a 55.76% increase from fiscal 2023.
- VAXCYTE, INC. operating lease, payments for fiscal 2023 was $7.39M, a 37.51% increase from fiscal 2022.
- VAXCYTE, INC. operating lease, payments for fiscal 2022 was $5.37M, a 481.60% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.25M 10-Q · filed 2026-08-05 | $6.96M 10-Q · filed 2026-08-05 | $10.36M derived: sum of 3 quarters · filed 2026-08-05 | $13.49M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $3.71M 10-Q · filed 2026-05-06 | $7.11M derived: sum of 2 quarters · filed 2026-05-06 | $10.23M derived: sum of 3 quarters · filed 2026-05-06 | $13.35M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $3.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $6.53M derived: sum of 2 quarters · filed 2026-02-24 | $9.64M derived: sum of 3 quarters · filed 2026-08-05 | $12.73M 10-K · filed 2026-02-24 |
| 2025-09-30 | $3.13M 10-Q · filed 2025-11-04 | $6.25M derived: sum of 2 quarters · filed 2026-08-05 | $9.33M 10-Q · filed 2025-11-04 | $12.44M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $3.12M 10-Q · filed 2026-08-05 | $6.20M 10-Q · filed 2026-08-05 | $9.31M derived: sum of 3 quarters · filed 2026-08-05 | $12.92M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $3.08M 10-Q · filed 2026-05-06 | $6.19M derived: sum of 2 quarters · filed 2026-05-06 | $9.80M derived: sum of 3 quarters · filed 2026-05-06 | $12.19M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $6.72M derived: sum of 2 quarters · filed 2026-02-24 | $9.11M derived: sum of 3 quarters · filed 2026-02-24 | $11.51M 10-K · filed 2026-02-24 |
| 2024-09-30 | $3.61M 10-Q · filed 2025-11-04 | $6.00M derived: sum of 2 quarters · filed 2025-11-04 | $8.41M 10-Q · filed 2025-11-04 | $10.77M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $2.39M 10-Q · filed 2025-08-06 | $4.78M 10-Q · filed 2025-08-06 | $7.16M derived: sum of 3 quarters · filed 2025-08-06 | $8.83M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $2.39M 10-Q · filed 2025-05-07 | $4.77M derived: sum of 2 quarters · filed 2025-05-07 | $6.44M derived: sum of 3 quarters · filed 2025-05-07 | $8.11M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $2.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $4.05M derived: sum of 2 quarters · filed 2025-02-25 | $5.72M derived: sum of 3 quarters · filed 2025-02-25 | $7.39M 10-K · filed 2025-02-25 |
| 2023-09-30 | $1.67M 10-Q · filed 2024-11-05 | $3.34M derived: sum of 2 quarters · filed 2024-11-05 | $5.01M 10-Q · filed 2024-11-05 | $6.64M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $1.67M 10-Q · filed 2024-08-06 | $3.34M 10-Q · filed 2024-08-06 | $4.97M derived: sum of 3 quarters · filed 2024-08-06 | $6.60M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $1.67M 10-Q · filed 2024-05-08 | $3.30M derived: sum of 2 quarters · filed 2024-05-08 | $4.93M derived: sum of 3 quarters · filed 2024-05-08 | $6.52M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $3.26M derived: sum of 2 quarters · filed 2024-02-27 | $4.85M derived: sum of 3 quarters · filed 2024-02-27 | $5.37M 10-K · filed 2024-02-27 |
| 2022-09-30 | $1.63M 10-Q · filed 2023-11-06 | $3.22M derived: sum of 2 quarters · filed 2023-11-06 | $3.74M 10-Q · filed 2023-11-06 | $3.84M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $1.59M 10-Q · filed 2023-08-08 | $2.11M 10-Q · filed 2023-08-08 | $2.21M derived: sum of 3 quarters · filed 2023-08-08 | $2.56M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $621.00K 10-Q · filed 2023-05-08 | $625.00K derived: sum of 2 quarters · filed 2023-05-08 | $975.00K derived: sum of 3 quarters · filed 2023-05-08 | $1.32M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $354.00K derived: sum of 2 quarters · filed 2023-02-27 | $701.00K derived: sum of 3 quarters · filed 2023-02-27 | $924.00K 10-K · filed 2023-02-27 |
| 2021-09-30 | $350.00K 10-Q · filed 2022-11-07 | $697.00K derived: sum of 2 quarters · filed 2022-11-07 | $920.00K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $347.00K 10-Q · filed 2022-08-08 | $570.00K 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $223.00K 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |